News | Capricorn Partners | Capricorn Partners

2023

Confo Therapeutics enters into collaboration agreement with Daiichi Sankyo to discover novel medicines for CNS diseases

30 March 2023

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

2 March 2023

2022

Filip Pintelon to represent Capricorn on the board of iSTAR Medical

30 November 2022

Capricorn Health-tech Fund supports its portfolio company iSTAR Medical entering into a Strategic Alliance with AbbVie for the Treatment of Glaucoma

20 July 2022

Capricorn Partners prepares its future further with a restyled logo and a new website

27 January 2022

2021

iSTAR Medical receives US FDA approval to start pivotal trial for MINIject in glaucoma patients

15 July 2021

Nexstim extends agreement with Canadian distributor and receives order for three NBT® systems

25 May 2021

Nexstim granted authorization for commercial distribution of NBS system in Australia

18 May 2021

Impressive new study results suggest potential new therapeutic use for Nexstim SmartFocus® nTMS in postsurgical rehabilitation of Paresis

17 May 2021

Confo Therapeutics awarded € 1 million VLAIO grant for pre-clinical development of CFTX-1554, an AT2R modulator for the treatment of neuropathic pain

30 March 2021

Nexstim gives an update on its promising treatment results of Major Depressive Disorder

12 March 2021

Mainstay Medical announces commercial launch of ReActiv8® in Australia

8 March 2021

1
2
3
4
...
5